). Integrated analysis of these data demonstrates that each mutant regulator establishes a specific transcriptional and signaling network unrelated to that seen in normal cells, sustaining the expression of unique sets of genes required for AML growth and maintenance.
A cute myeloid leukemia (AML) is characterized by blocked myeloid lineage differentiation and accumulation of leukemic blast cells. It is a highly heterogeneous disease caused by different types of genetic alterations that affect signaling pathways as well as transcriptional and epigenetic regulators [1] [2] [3] . Recurrent alterations include loss-of-function substitutions in transcription factors controlling hematopoietic development, such as RUNX1, GATA2 or C/EBPα (ref. 4 ), and gain-of-function substitutions in signaling molecules such as FLT3, KIT, JAK2 and NRAS, which regulate inducible transcription factors such as NF-κ B, STAT or AP-1 family members [5] [6] [7] . The most common FLT3 alterations are internal tandem duplications (FLT3-ITD), which give rise to a constitutively active growth factor receptor 8, 9 and often occur together with nucleophosmin 1 (NPM1) alterations. Another major group of mutations alters genes encoding epigenetic and chromatin regulators 10, 11 that have widespread roles in development and differentiation by controlling establishment, maintenance and extinction of lineage-specific gene expression programs. These include regulators of histone and DNA methylation such as MLL, EZH2, TET2, DNMT3A, IDH1 and IDH2 (refs [11] [12] [13] [14] [15] [16] [17] ). In normal cells, all common mutation targets cooperate to control the finely balanced gene expression changes that are essential for cell differentiation and lineage commitment.
Transcription factors interact with defined target gene sequences and recruit epigenetic regulators to program specific chromatin states and mediate the coordinated activation or deactivation of cis-regulatory elements driving gene expression 18, 19 . Distal cis-regulatory elements interact directly with promoter elements, an arrangement that is both dynamic and robust 20, 21 . From global studies examining a few selected types of AML, we know that their gene expression patterns and epigenetic landscapes differ from those in normal cells [22] [23] [24] [25] [26] [27] . However, how the disruption of specific transcription factor activity leads to a specific pattern of aberrant chromatin programming and changes in gene expression in AML has remained unclear. It has not been established at the global level which cis-regulatory elements are affected in activity in different types of AML, how their activity is altered in subjects carrying specific transcription factor and signaling alterations, or which factors maintain their transcriptional networks.
Here we addressed these questions by collecting transcriptome, digital footprinting and chromatin conformation capture data from purified leukemic blasts from AML subjects with defined transcription factor and signaling molecule alterations and defined the components of AML subtype-specific regulatory circuitries. Our study provides a comprehensive resource on the transcriptional networks of different AML subtypes, highlighting pathways required for tumor maintenance.
Results
AML subtypes adopt unique chromatin landscapes. To examine how specific transcription factor and signaling substitutions alter the epigenome of AML, we purified leukemic blast cells from bone marrow or peripheral blood samples from AML subjects (Fig. 1a) . After determining the mutation status ( Supplementary Table 1 ), we Articles NATURE GENETICS selected a cohort of subjects with defined mutations, which included RUNX1 mutations affecting RUNX1 DNA binding (D-type) or lacking the trans-activating domain (T-type); t(8;21) translocations fusing the DNA-binding domain of RUNX1 to the co-repressor ETO; inv (16) , which fuses CBFβ to smooth muscle myosin heavy chain 11 protein; mutations of both alleles of the CEBPA gene (CEBPA (× 2)
Patient code
Signaling NPM1 Chrom. RUNX Other mutations RUNX1-T/JAK-2 JAK2 RUNX1 T ET2x2, TP53 RUNX1-D/JAK-1 JAK2 tri (21, 9) RUNX1 IDH2, SRSF2 RUNX1-D-5 RUNX1 IDH1, BCORL1x2, SRSF2x2 RUNX1-T/CEBPA- 6 NRAS tri ( FLT3-ITD NPM1 GATA2, DNMT3A ITD-1 FLT3-ITD DNMT3A, TET2x2, BCOR, TP53 ITD/NPM1-5 FLT3-ITD NPM1 DNMT3A, BCOR ITD-3 FLT3-ITD DNMT3A ITD/NPM1-6 FLT3-ITD NPM1 WT1, DNMT3A, TET2, PHF6 ITD-2 FLT3-ITD tri (13) DNMT3A, TET2 ITD/NPM1-1 FLT3-ITD NPM1 WT1, DNMT3A ITD/NPM1-3
CEBPAx2, GATA2, TET2 CEBPA(x2)-2 CEBPAx2, GATA2 CEBPA(x2)- 
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whereby one mutation leads to loss of DNA-binding activity 28 and FLT3-ITD with or without NPM1 mutations. We performed RNA-seq ( Supplementary Fig. 1a ) and high-read-depth DNase I-seq ( Fig. 1b ) to map DNase I hypersensitive sites (DHSs) on 29 samples comprising seven major groups, and at least one analysis on 12 additional samples, carrying mutations of genes such as NRAS, CBL, JAK2, SRSF2 or the inv(3) translocation ( Supplementary Table 1 ). One subject with non-Hodgkin lymphoma carried a RUNX1 mutation (RUNX1-T-7). Samples were compared to CD34 + mobilized peripheral blood stem cells (PBSCs) from two healthy individuals and to cord blood CD34 + cells. To provide the community with a data resource, we established an online database containing multiple data sets including a genome browser (see Data Availability). Unsupervised clustering revealed that distal DHSs formed different groups according to their alteration class ( Fig. 1c ). Samples with FLT3-ITD and/or NPM1 alterations represented one major group with subclusters for subjects with NPM1 alterations or carrying two FLT3-ITD alleles, but excluding a FLT3-ITD subject carrying a RUNX1 mutation. DHSs from the t(8;21), inv (16) and CEBPA double mutant subjects clustered as discrete groups within a larger group, indicating that these mutations affect similar pathways. Examples of these patterns can be seen in Supplementary Fig. 1b . DHSs from subjects with RUNX1 alterations were more heterogeneous and clustered with the PBSCs and the inv(3) subjects. The non-Hodgkin lymphoma (RUNX1-T-7) and NPM1/RAS-3 patterns were unrelated to any of the others. We further validated our findings by analyzing an independently derived published data set based on the assay for transposase-accessible chromatin using sequencing (ATAC-seq) 25 , confirming that alterations in FLT3 underpin one major component of the clustering ( Supplementary Fig. 2a ). In contrast, the presence or absence of mutations of genes encoding epigenetic regulators such as DNMT3A did not influence chromatin accessibility levels ( Supplementary Fig. 2b ) or gene expression (data not shown). Our mutation analyses showed no indication of the presence of confounding major subclones in purified undifferentiated AML cell populations, as mutations were present at close to either 50% or 100% allele frequency (Supplementary Data 1).
Unsupervised clustering analysis of RNA-seq data from the same subjects as well as direct comparisons between individual samples (Supplementary Figs. 1c and 2c) revealed strong correlations between mutation-specific chromatin landscapes and mutationspecific differential gene expression, as exemplified by POU4F1 and FOXC1, where mRNA patterns correlated well with chromatin profiles ( Supplementary Fig. 1d ). We identified distinct patterns of expression for specific transcription factor-encoding genes in different AML types ( Supplementary Fig. 2d ). For example, various homeodomain gene family members (HOX, NKX, IRX and PBX families) were upregulated in the FLT3-ITD-and NPM1-altered subjects. Our comparative analyses show that aberrant transcription factors and chronic signaling impose distinct alteration-specific patterns of chromatin accessibility and gene expression, irrespective of the presence of additional mutations.
AML-specific clustering of distal cis-regulatory elements.
We next examined the active cis-regulatory elements specific for each AML subtype by defining the union of all AML-specific DHSs as compared to CD34 + PBSCs and performing k-mean clustering to identify unique and common DHSs shared among subjects; this identified 20 distinct DHS clusters ( Fig. 2a ). Less than half of these DHSs were found in any of the Corces et al. progenitor ATAC-seq data sets 25 and the percentage overlap varied substantially between clusters (range of 2-40%). We verified mutation-specific clustering behavior of our samples by comparing them with a recently published AML histone H3K27 acetylation data set 26 showing similar patterns for FLT3-ITD, RUNX1 and CEBPA double mutations ( Supplementary Fig. 3d ). We also defined mutation-specific groups of deregulated DHSs that were shared between the specific members of each of the seven major mutation groups defined in Supplementary Table 1 ( Supplementary Fig. 4a ,b) which were distributed between both the mutation-specific clusters and the shared clusters ( Fig. 2b ) and were associated with differentially expressed genes (Supplementary Data 2). Again, the t(8;21), inv (16) and CEBPA groups showed similar patterns whereby 914 upregulated DHSs were shared among the three groups ( Supplementary Fig. 4a ). The FLT3-ITD, FLT3-ITD/NPM1 and NPM1 alteration groups showed substantial overlap with 942 shared DHSs, and with only 19% of these DHSs included in the 914 FLT3-ITD/NPM1-specific group. These AML-specific patterns showed little similarity to normal myeloid differentiation as the majority of these specific sites were not upregulated in granulocyte-monocyte progenitor cells relative to PBSCs (Supplementary Note Fig. SN2b ).
The presence of specific DHSs was strongly correlated with the upregulation of their associated genes (Supplementary Data 3 and Supplementary Fig. 4c ), as exemplified by two DHSs at POU4F1 ( Supplementary Fig. 4d ). Supplementary Fig. 4e shows examples of AML type-specific upregulated transcription factor genes, and growth factor or receptor genes, that were associated with AML type-specific DHSs (Supplementary Data 4). The gene expression patterns of such genes were validated using publicly available data sets ( Supplementary Fig. 5 ).
AML-specific transcription factor binding patterns.
To identify transcription factors associated with different chromatin patterns, we analyzed high-read-depth DNase I-seq data using our Wellington digital footprinting algorithm 29 . Because closely related factors recognize identical sequences, we compiled a nonredundant database of motifs (Supplementary Table 2 ) and selected representative motifs encompassing each transcription factor family, as defined in more detail on our web server (see URLs). Examples of footprints are depicted for NFI and ETS motifs at the MDFI locus in FLT3-ITD/NPM1-altered AML ( Fig. 3a ) and for RUNX, NFAT and C/EBP motifs at the C3AR1 locus in t(8;21) and CEBPA-altered AML ( Supplementary Fig. 6a ). The majority of AML type-specific DHSs within the 20 AML-specific DHS clusters contained footprints ( Supplementary Fig. 6b ). For validation, we compared RUNX motif footprints with publicly available RUNX1 ChIP data from our studies (FLT3-ITD/NPM1, ref. 24 ; t(8;21), ref. 30 ) and others (inv(16), ref. 31 ) ( Supplementary Fig. 6c ). Some 60-85% of footprinted RUNX motifs occurred in regions shown to bind RUNX1.
We next evaluated occupied motif enrichment in the 20 AML subtype-specific DHS clusters (Fig. 3b ), and found that motif occupancy patterns were highly AML type-specific. For example, the FLT3-ITD/NPM1-specific clusters 5 and 19 are enriched for occupied HOX, FOX/E-box and NFI motifs and correlate with upregulation of FOXC1, NFIX and multiple homeodomain genes ( Supplementary  Fig. 2d ). Occupied AP-1 motifs are enriched in multiple clusters (01, 05, 07, 12, 13, 18 and 19), many of which were found in AML with signaling mutations. Because AP-1 factors mediate MAP kinase (MAPK) signaling, this enrichment indicates widespread activation of this signaling pathway in FLT3-ITD AML 24 and other AML types. Finally, we observed significant POU4F1 motif occupancy in clusters 02 and 20, which contained samples from t (8;21) and CEBPA double mutant subjects, but nowhere else ( Fig. 3b ). POU4F1 is aberrantly expressed in t(8;21) cells 32 , but has so far not been linked to CEBPA double mutations. We observed a similar differential occupancy pattern when footprints were clustered according to mutation-specific groups of DHSs ( Supplementary Fig. 6d ). C/EBP motifs in AMLs with CEBPA double mutations showed no reduction in overall motif occupancy, suggesting compensation by other C/EBP family members.
To examine the position of transcription factor occupancy patterns within the hematopoietic hierarchy, we determined the Articles NATURE GENETICS correlation of the presence of footprints specific for AML subtypes with accessible chromatin regions present in precursor cells ( Fig. 4) 25 . This analysis revealed unique factor occupancy patterns in AML cells compared to normal progenitors. For example, HOX motifs within open chromatin regions observed in hematopoietic stem cells (HSCs), multipotent progenitor (MPP) cells and megakaryocyte-erythroid progenitor (MEP) cells are occupied in the FLT3-ITD/NPM1 and RUNX1 groups, but not in the t(8;21) group, indicating an early block in differentiation (see also Supplementary Note Fig. SN1b ). Many of the samples, including NPM1, FLT3-ITD/ NPM1 and t(8;21) cells, display high AP-1 motif occupancy which is normally only seen in monocytes. POU4F1 is expressed in HSCs, multipotent progenitor cells (MPPs), megakaryocyte-erythrocyte progenitor cells (MEPs) and common lymphoid progenitor cells (CLPs) 25 and its binding motifs are occupied in t(8;21) and CEBPA double mutant cells, yet these AML cells also show strong occupancy of C/EBP motifs, which is normally a hallmark of granulocyte-monocyte progenitor cells and monocytes. In summary, our digital footprinting analysis shows that (1) each AML subtype uses a different combination of factors to bind to elements shared with different types of precursor cells and (2) lineage-unrelated expressed transcription factors such as FOXC1, NFIX and POU4F1 participate in such cooperation.
AML subtype-specific cis-element interactions. The construction of gene regulatory networks relies on linking cis-regulatory elements to their respective promoters 33 . We therefore examined (1) whether the differential activity of cis-regulatory elements in AML subtypes led to the formation of alternate cis-element interactions, and (2) which transcription factor families were involved in such interactions, by using promoter-capture chromosomal structure analysis (CHi-C) 34 . We analyzed cells from relapse subject t(8;21)-1R ( Supplementary Table 1 ), which maintained a gene regulation network similar to the presentation sample t(8;21)-1 ( Fig. 1c and Supplementary Figs. 1c and 7a ), and from a subject carrying a FLT3-ITD/NPM1 alteration (ITD/NPM1-2, Supplementary Table 1 ). 
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We compared these data to a data set derived from human CD34 + cells 34 . Intrachromosomal interactions did not differ at the global level ( Supplementary Fig. 7b ) and the organization into topologically associated domains containing the DHSs was unaffected by the type of AML ( Supplementary Fig. 7c ).
The proportion of DHSs involved in AML subtype-specific interactions varied between DHS clusters ( Supplementary Fig. 7d ), and ~40% of all promoters showing differential interactions were associated with expressed genes ( Supplementary Fig. 7e ,f). A direct comparison between the CHi-C data from the two subjects ( Supplementary Fig. 7g ) showed that (1) differential interactions were correlated with differential DHS patterns and (2) a differential set of genes was expressed with different gene ontology (GO) terms (Supplementary Data 5) as exemplified by the KLF2 gene, which is differentially expressed in FLT3-ITD, t(8;21) and CD34 + cells ( Supplementary Fig. 7h ).
On average 80% of all DHSs mapped in t(8;21) AML, FLT3-ITD AML and CD34 + cells participated in interactions ( Supplementary  Fig. 8a ). An average of 17% of interactions were AML type-specific and not present in CD34 + PBSCs ( Supplementary Fig. 8b ). To identify the transcription factor families involved in regulating differential interactions we determined the proportions of enriched occupied motifs in DHSs underlying these interactions ( Supplementary Fig. 8c ). These analyses suggest that hematopoietic transcription factors such as RUNX, ETS and C/EBP family members and transcription factors specifically expressed in AML subtypes participate in ID   TCF3  SNAI  SMAD  HIF1A  XBP1  GLI  MYC/MAX  HES  HINFP  KLF  Sp1  TFDP1  CAMTA  AHR  NRF1  TFCP2  EGR  CREB/ATF  PAX5  NF-kB  RXR  PPAR  MITF  PU.1  RAR  POU4F1  HHEX  GATA  TGIF1  SOX  IRF  PRDM1  MEF2  SRF  NFY  NR  ETS  ETS:Ebox  PKNOX1  TAL1  RFX  RUNX  LEF1  REST  CTCF  HIC1  ESRRA  THR  ESR1  BCL6  STAT5  HOX  FOX:Ebox  STAT3  NF1  IKZF  TEAD  MAF  NFE2  AP-1  VENTX  IRX  MEIS  OCT  PBX  MNX1  CUT  FOX  NFAT  STAT6  ST18  HBP1  MYB  C/EBP  NFIL3  GFI1B  HSF1 Articles NATURE GENETICS differential interactions in both AML types, together with the AP-1 factor family. In FLT3-ITD AMLs this included HOX proteins and factors occupying FOX/E-box motifs. In the t(8;21) AMLs this included proteins binding to FOX and POU4F1 motifs.
Differential interactions drive AML-specific gene expression.
The majority of DHSs underlying interactions among the three data sets and those of individual subjects were shared with an average of 80% overlap ( Supplementary Fig. 8d ), confirming that the global transcriptional network of related cells is highly related 35, 36 . Subtypespecific DHSs participating in interactions were enriched within related groups, but not within unrelated groups ( Supplementary  Fig. 8e ), confirming that the two subjects were representative of those groups. For both the FLT3-ITD/NPM1 and the t(8;21) sample the nearest promoter accounted for 65-74% of AML type-specific interactions associated with genes that are upregulated in AML as compared to CD34 + cells ( Fig. 5a ). We observed similar results for each of the 20 DHS clusters ( Supplementary Fig. 8f ).
To integrate differential interaction data, digital footprinting data and gene expression data, we assigned the respective DHSs to their interacting promoters as described in Fig. 5b . GO-term and Kyoto Encyclopedia of Genes and Genomes (KEGG)-pathway analyses of expressed genes in the two types of AML ( Fig. 5c-f ) revealed an AML subtype-specific core signature of genes driven by specific cis-regulatory elements (for an extended gene list see Supplementary Data 5). For both AML samples these included genes involved in regulating pro-inflammatory pathways. FLT3-ITD cells also displayed an activated MAPK signaling signature, whereas the t(8;21) signature also included RAP, RAS, PI3K and FOXO signaling genes. FOXO1 is part of the t(8;21) preleukemic maintenance program 37 . More than 50% of all genes within these pathways were targets of RUNX1-ETO ( Fig. 5g) 30 , thereby linking them to the actual driver mutation. A similar percentage of the genes within the FLT3-ITD/NPM1 core pathway are bound by RUNX1 ( Fig. 5g ), which is upregulated in FLT3-ITD 24 (Supplementary Data 5). Because ~83% of the DHSs involved in interactions in each of the three samples ( Supplementary Fig. 8g ) were shared, we merged all three CHi-C data sets and used these data to assign the DHSs from the 20 clusters ( Fig. 2a ) to their respective promoters. The remaining 17% of DHSs were assigned to the nearest promoter. GO-term and KEGG-pathway analyses of such genes (listed in Supplementary Data 6) again showed activation of genes connected with signaling processes, such as inflammatory response, regulation of MAPK activity and cytokine regulation in all types of AML.
AML subtypes display unique transcription factor networks.
Constitutive and inducible transcription factors form regulatory networks by interacting with their own and/or other regulatory genes 35 . Cancer cells maintain a stable regulatory network, indicating that the expression of each network member is tightly controlled and remains in balance. Consequently, perturbation of the network components maintaining this balance may destabilize leukemic cells, thus offering new therapeutic options. We therefore combined footprinting, transcription factor gene expression and, where possible, CHi-C data to construct transcription factor networks in normal CD34 + cells and the different AML subtypes by linking occupied binding motifs within transcription factor genes to the specific transcription factor families recognizing these motifs. The transcription factor families involved and the full network structure for each cell type without filtering can be studied in detail on our webserver (see URLs). By comparing the different AML subtypes with normal CD34 + cells, we identified interactions among transcription factor subsets and their genes that were either shared between AMLs and CD34 + cells ( Supplementary Fig. 9 ) or were subtype specific ( Fig. 6 ). These results suggest that the AP-1 family network is of high regulatory relevance for all AML subtypes ( Fig. 6b-g ). POU4F1 and HLH family factors recognising MYC/MAX-type E-boxes formed prominent nodes in t(8;21) AML only, whereas HOX proteins, FOXC1, NFIX and the MAF family formed specific nodes in FLT3-ITD and NPM1 AML. Specific nodes and edges were also part of the normal precursor program
Enrichment of specific motifs footprinted in AML cells within ATAC peaks present in progenitor cells 
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( Supplementary Fig. 9 ). For example, the link between the C/EBP family and NFIL3 was shared between the FLT3-ITD/NPM1 cells ( Fig. 6f ) and CD34 + PBSCs ( Supplementary Fig. 9f (16)specific transcription factor network. e, Mutant RUNX1-specific transcription factor network. f, FLT3-ITD/NPM1-specific transcription factor network. g, NPM1-specific transcription factor network. Factor families binding to the same motif as shown in Supplementary Table 2 form a node contained within a circle. Arrows pointing outward from entire node highlight footprinted motifs in individual genes generated by any member of this factor family whereby the footprint was annotated to the gene using the CHiC data where possible, or otherwise to the nearest gene. For selected nodes, the name of the underlying motif is highlighted in large letters. The expression level (FKPM) of the individual genes is depicted in white (low) or red (high) color. A smooth orange ring around the circle indicates a gene that is specifically upregulated in this type of AML compared to CD34 + PBSCs and/or other AML types; a dotted circle indicates a gene that is upregulated as compared to CD34 + cells.
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Transcription factors contributing to AML-specific growth. We next validated the importance of specific transcription factors forming network nodes. To this end we transduced three different AML cell lines and primary FLT3-ITD AML cells with lentiviral vectors encoding short hairpin RNAs (shRNAs) targeting POU4F1 (specific for t(8;21)) or NFIX and FOXC1 (specific for FLT3-ITD). NFIX has a role in myeloid lineage specification 38 but has not been linked to specific mutation types. FOXC1 is an oncogene in its own right 39 and it is overexpressed in AMLs with FLT3-ITD alterations 24 . However, NFIX and FOXC1 have not been linked to the maintenance of the FLT3-ITD AML. We transduced two distinct shRNA constructs per gene into FLT3-ITD and t(8;21) cell lines, which significantly reduced the corresponding transcription factor transcript and protein levels as compared to the control ( Supplementary  Fig 10a-f ). Knockdown of POU4F1 ( Supplementary Fig. 10a,d) inhibited the proliferation of t(8;21) + Kasumi-1 cells ( Fig. 7a and Supplementary Fig. 10g ), confirming our previous findings 32 . Expression of NFIX shRNAs ( Supplementary Fig. 10b,e ) impaired the proliferation of FLT3-ITD + MV4-11, but not FLT3-ITD -Kasumi-1 cells (Fig. 7b,c and Supplementary Fig. 10h,i) . We next tested the effect of shRNA knockdown of these genes on the colony-forming ability of CD34 + FLT3-ITD/NPM1 mutant subject cells compared to CD34 + PBSCs. Both NFIX and FOXC1 shRNA constructs led to lower colony-forming ability of AML cells compared to a missmatch shRNA contol, but no effect was observed in normal CD34 + HSP cells ( Fig. 7d,e ).
Our network analysis suggests that the AP-1 family is of general importance for all AML subtypes examined, in addition to subtype-specific transcription factors such as POU4F1 or NFIX. AP-1 is a heterodimer formed by members of the FOS, JUN, ATF, CREB and JDP families of transcription factors, thus it is challenging to target by defined RNA interference approaches. To this end, we transduced AML cells with an inducible version of a dominant negative FOS (dnFOS) protein 40, 41 . Doxycycline-mediated induction of dnFOS significantly inhibited proliferation of both t(8;21) + Kasumi-1 cells and FLT3-ITD-expressing MV4-11 cell lines (Fig. 7f,g and Supplementary Fig. 10j,k) ; it also inhibited the colonyforming ability of primary CD34 + FLT3-ITD cells but not that of CD34 + hematopoetic stem and progenitor (HSP) cells (Fig. 7h,i and Supplementary Fig. 10l ).
Finally, we examined the importance of AP-1 for leukemia propagation in vivo by transplanting either Kasumi-1 or MV4-11 cells expressing a doxycycline-inducible dnFOS into immunodeficient mice, followed by randomization into doxycycline-treated and untreated groups. In the case of Kasumi-1 transplantation, six of seven animals in the control group, but only two animals in the doxycycline-treated group, developed granulosarcomas (Fig. 7j) . Neither of the latter two tumors expressed dnFOS after doxycycline treatment (data not shown), indicating that the transgene was silenced. Doxycycline treatment of mice transplanted with FLT3-ITD MV4-11 cells harboring the dnFOS transgene inhibited the development of leukemia, whereas all untreated mice rapidly developed tumors and were killed (Fig. 7k ). Taken together, these findings demonstrate the importance of AP-1 for several AML subtypes and emphasize the potential of transcriptional network analyses to predict transcription factors crucial for malignant propagation.
Discussion
In this study we defined how aberrantly expressed transcription factors and signaling molecules shape the epigenetic landscape of different subtypes of human AML. We show (1) that it is possible to use high-quality DNase I footprinting analyses of purified AML blast cells to identify AML subtype-specific transcription factor networks, (2) that such transcription factor networks highlight a dependence on specific factors for leukemic growth and (3) that the global activation of signaling pathways parallels a growth dependence on AP-1 activity in multiple types of AML. Our comprehensive integration of multi-omics data reveals a strong connection among leukemic classifier mutations, networks of transcription factors and signaling components in primary AML. Moreover, by mapping cis-element promoter interactions by CHiC, we assigned the majority of genes of all analyzed subtypes to their correct promoter. Different types of AML have been classified by their gene expression and DNA-methylation patterns 42, 43 , revealing the existence of specific gene regulatory networks. Our work now defines these networks in detail, and shows that leukemic drivers determine the regulatory phenotype by establishing and maintaining specific gene regulatory and signaling networks that are distinct from those in normal cells. Induced and aberrantly expressed transcription factors are not bystanders, but are important for network maintenance and leukemic growth; this observation highlights new therapeutic opportunities for targeted treatment.
The full set of target genes of RUNX1-ETO in t(8;21) is known and the t(8;21)-specific epigenome and transcription factor binding pattern has been extensively characterized 44 . Multiple target genes relevant for the maintenance of the leukemogenic state have been identified, including FOXO1, UBASH3B, POU4F1 and LAT2, together with the members of the RUNX1-ETO complex 22, 32, 37, [45] [46] [47] , and our current comparative study has identified multiple new network components. However, for the other types of AML, in particular for FLT3-ITD, such knowledge was not available. Here, we identified a number of signaling and transcriptional components that distinguish FLT3-ITD from normal blasts and from other types of AML, providing a rich resource for combinatorial therapy approaches. We examined the contribution to leukemic growth for two genes with AML subtype-specific activity (NFIX and FOXC1) and showed that their elimination led to reduced growth and colony-forming ability of AML but not normal cells, confirming that AML maintains an aberrant transcriptional network required for survival.
The AP-1 factor family has an important role in many types of tumors 48 and our study shows that it is of major importance for AML. FLT3-ITD MV4-11 cells have abundant levels of nuclear AP-1, and FLT3-ITD target genes such as CCNA1 are suppressed by MAPK inhibitors in these cells 24 . We have recently shown that JUN scores highly in a siRNA dropout screen examining the requirements for tumor development in t(8;21) AML. 49 FOS has an important role in resistance to the inhibition of another leukemic oncoprotein, the BCR-ABL kinase in chronic myeloid leukemia by activating compensatory signaling pathways 50 . Because several growth factor and stress signal cascades feed into AP-1, targeted inhibition of all AP-1 binding may prevent resistance via rewiring of signaling pathways.
In the classical mechanism of two-step leukemogenesis, a substitution altering a differentiation trajectory cooperates with signaling alterations directing leukemic growth 10, 11 . According to this definition, alterations in transcription factors, which program chromatin directly, and epigenetic regulators, which define the epigenetic landscape upon which transcription factors act, fall into the first category and the FLT3-ITD alteration falls into the second. However, these distinctions are now becoming blurred because from the viewpoint of gene regulation, growth factor receptors strongly influence transcriptional activity via inducible transcription factors, as exemplified by AP-1 family members. These factors have a dominant role in driving the differentiation trajectory as they display an AML subtype-specific occupancy signature that is not influenced by the presence or absence of epigenetic regulator alterations (in this case DNMT3A) 24 . This is not to say that alterations in epigenetic regulators do not influence the developmental trajectory of AML and clinical outcomes, as shown in CBF AML 51 , because AML cells with such alterations acquire an altered DNA methylation landscape that probably influences transcription factor binding 52 . However, our data show that leukemic phenotype 
Articles
NATURE GENETICS
and self-renewal of different types of AML are defined by differentially activating a multitude of different and often lineage-unrelated signaling pathways and by expressing lineage-unrelated transcription factors. From the viewpoint of finding therapeutic targets, identifying such alteration-specific pathways will offer an opportunity to eliminate their specific maintenance program by targeting multiple pathways simultaneously. Our study takes a first step toward this goal. Mutations were identified by one of two different methods. The first batch of subjects were assayed by targeted exon sequencing of 55 cancerassociated genes using 1,212 pairs of previously defined PCR primers 24 for amplification using a RainDance Technologies platform. The mutation sequence data from this screen was analyzed using algorithms to detect either nucleotide variants using the Genome Analysis Toolkit 53 or insertions and deletions using Pindel 53 . Mutations were also screened against the COSMIC database of previously observed mutations (see URLs). Subsequent samples were assayed using the Illumina Trusight myeloid panel of primers and processed by approaches similar to those used for the first batch. All identified mutations are listed in Supplementary  Table 1 . Some of these subjects were also included in a previous publication from our laboratory, using different subject identification codes 24 than those used in the current study.
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Cell lines. Cell lines were cultured in an incubator at 37 °C in GIBCO 1640 RPMI plus Glutamax medium supplemented with 10% heat-inactivated FCS (GIBCO), 100 U ml -1 penicillin and 100 mg ml -1 streptomycin.
Growth curve measurements. 250,000 MV4-11 or Kasumi-1 cells were cultured in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% FCS, 2 mM l-glutamine, 100 U ml -1 penicillin and 100 mg ml -1 streptomycin. Cells were counted with Trypan blue exclusion and split every 3 d to maintain them in the log phase of growth. For the inducible dnFOS, cells were counted and split every 2 d and 1.5 µ g ml -1 of doxycycline was added.
Coculture of primary cells with MS-5 feeders.
Primary cells were maintained in coculture with MS-5 cells 54 Briefly, cells were cultured in LTC medium (α -minimum essential medium (Lonza) supplemented with heat-inactivated 12.5% FCS (Gibco), heat-inactivated 12.5% horse serum (Gibco), penicillin and streptomycin, 200 mM glutamine, 57.2 μ M β -mercaptoethanol (Sigma) and 1 μ M hydrocortisone (Sigma) supplemented with 20 ng ml -1 interleukin-3 (IL-3), granulocyte colony-stimulating factor and thrombopoietin in flasks precoated with MS-5 cells.
Lentiviral transduction and shRNA treatment. LEGO-iG shRNAs were generated by cloning shRNAs ( Supplementary Table 3 ) into the LEGO-iG vector 55 . LEGO-iG-dnFOS was generated by cloning the dnFOS insert, originally generated by Charles Vinson (National Cancer Institute, Bethesda, MD, USA 40) into the LEGO-iG backbone. Inducible dnFOS was cloned into a pENTR backbone and then Gateway cloning was used to insert that into the Tet-on plasmid pCW57.1 (David Root, Addgene plasmid 41393). Backbone vectors LEGO-iG and inducible dnFOS were then used to generate lentiviral particles using packaging and envelope genes on four separate plasmids: TAT, REV, GAG/POL and VSV-G 56 . For virus production, Human embryonic kidney 293T (HEK293T) cells were cultured in DMEM supplemented with 10% FCS, 2 mM l-glutamine, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin and 0.11 mg ml -1 sodium pyruvate, and were seeded to achieve 70-80% confluence at time of transfection. HEK293T cells were transfected using calcium phosphate co-precipitation of the five plasmids (LEGO-iG with TAT, REV, GAG/POL and VSV-G) at a mass ratio of 24 μ g:1.2 μ g: 1.2 μ g:1.2 μ g:2.4 μ g per 150 mm-diameter plate of cells. Viral supernatant was harvested after 24 h and subsequently every 12 h for 36 h before concentration with Centricon Plus-70 100-kDa filter (Millipore), using the manufacturer's instructions. Concentrated viral particles were stored at 4 °C before lentiviral transduction. Cell lines were transduced with concentrated virus in the presence of 8 μ g ml -1 polybrene by spinoculation at 1,500g for 50 min. After 12-16 h incubation at 37 °C, viral medium was exchanged for fresh medium. FACS was performed to isolate GFP + cells 3 d after transduction.
Primary cell samples were defrosted 24 h before transduction and cocultured with MS-5 feeder cells in LTC medium. Six-well nontissue culture treated plates were coated with 24 μ g ml -1 retronectin (Takara Clontech) for 2 h before blocking with 2% BSA in PBS for 30 min. The blocking buffer was washed off with Hank's buffered salt solution (Gibco) containing 2.5% HEPES. Viral concentrate (1 ml) was applied to the retronectin-coated plate by centrifugation at 2,000g for 45 min, after which the concentrated viral supernatant was refreshed and the centrifugation repeated. Primary cells were suspended to a concentration of 1 × 10 6 cells ml -1 in the remaining viral supernatant, supplemented with 20 ng μ l -1 granulocyte colonystimulating factor, IL-3, thrombopoietin and 8 μ g ml -1 polybrene, and then added to the plate and transduced by spinoculation at 1,500g for 50 min. After 12-16 h incubation at 37 °C, viral medium was exchanged for fresh medium. FACS was performed to isolate GFP + cells 3 d after transduction.
Colony-formation assays of primary cells. Colony-formation assays were performed on sorted cells by seeding at 2,500 cells ml -1 in Methocult Express (Stem Cell Technologies). After 14 d colonies were counted.
Animal experiments. Immunodeficient Rag2 −/− Il2rγ −/− 129 × Balb/c (RG) mice were housed in the Comparative Biology Centre (Newcastle University) under specific pathogen-free conditions. All animal work was conducted in accordance with Home Office Project License PPL60/4552 by researchers who had completed approved Home Office training and held current personal licenses under the Animals (Scientific Procedures) Act 1986. Kasumi-1 pCW57.1-dnFOS cells were intrahepatically injected into 14 newborn (2-d old) RG mice at a cell dose of 2.5 × 10 5 cells per mouse as described 49 . At 12 d later, mice were randomized into two treatment groups, with one given 50 mg kg -1 doxycycline three times per week intraperitoneally in an unblended fashion until the experimental endpoint. MV4-11 pCW57.1-dnFOS cells were intrafemorally injected into RG mice at a cell dose of 5 × 10 5 cells per mouse followed by randomization into two groups. For the doxycycline group, doxycycline was added at 2 mg ml -1 for the initial 3 d and at 0.2 mg ml -1 subsequently to drinking water containing 2% sucrose. Controls were given water containing 2% sucrose. Animals were humanely killed upon clinical signs of illness or at defined experimental endpoints.
Quantitative PCR with reverse transcription. RNA was extracted using the Machery-Nagel Nucleospin kit. RNA (1 μ g) was used to make cDNA with 0.5 μ g oligo(dT) primer, Murine Moloney reverse transcriptase and RNase inhibitor (Promega) according to the manufacturer's protocol. PCR with reverse transcription was performed using Sybr Green mix (Applied Biosystems), at 2× dilution. Primers were used at 100 nM. A 7900HT system (Applied Biosystems) was used to perform quantitative PCR. Analyses were performed in technical duplicates using a standard curve derived from the untreated cell line.
Western blotting. Protein lysates from cell lines were analyzed by western blot. Relevant primary antibodies to FOXC1 (Cell Signaling Technology, 8758), NFIX (Invitrogen, PA5-31234) and POU4F1 (Santa Cruz Biotechnology, sc-8429) were used to detect target genes, and antibody to GAPDH (mouse anti-GAPDH, Abcam, ab8245; rabbit anti-GAPDH, Cell Signaling Technology, 2118L) was used as a housekeeping gene. Secondary antibodies mouse anti-rabbit horseradish peroxidase (Santa Cruz Biotechnology, sc-2054) and goat anti-mouse horseradish peroxidase (Jackson ImmunoResearch, 115-035-062) enabled detection and quantification by densitometry using Imagelab software and a GelDoc imager. The tumor mass of mice transplanted with Kasumi-1 pCW57.1-dnFOS with or without doxycycline was analyzed using a Mann-Whitney test as the distribution of data was not normal. This experiment was performed for n = 7 engrafted mice in each group (P = 0.0326, Mann-Whitney U = 8.5. The survival curve of mice engrafted with MV4-11 pCW57-dnFOS with or without doxycycline was analyzed with a Kaplan-Meier plot (n = 5 engrafted mice) using a Mantel-Cox chi-squared test (χ 2 = 8.097, degrees of freedom = 1, P = 0.0044) and yielding a Mantel-Haenszel hazard ratio of 14.08.
Statistical analysis of validation experiments. Validation experiments
RNA-seq library preparation.
RNA was extracted and analyzed from purified AML cells as described 23. DNase I-seq. DNase I digestions of permeabilized cells were performed as described 57 . Briefly, live cells were added directly to a solution of DNase I (DPFF, Worthington) in dilute Nonidet P40 and digested for 3 min at 22 °C, and the reactions were then terminated by addition of SDS to 0.5%. DNase I was typically used in the range of 2-6 μ g ml -1 with a final 1.5 × 10 7 cells ml -1 . DNase I-seq Articles NATURE GENETICS libraries were then prepared and validated essentially as described 30 . Libraries were run on Illumina sequencers.
Promoter capture HiC from subject AML blasts. AML cells from subject peripheral blood were first purified by density gradient centrifugation (Lymphoprep) and then using CD34 antibody-coupled beads. 5 × 10 7 t(8;21) blasts (subject t(8;21)-1R) and FLT3-ITD/NPM1 blasts (subject ITD/NPM1-2) were fixed in 37 ml of RPMI-1640 supplemented with 15% FBS and 2% formaldehyde for 10 min at room temperature. Glycine (6 ml of 1 M, 0.125 M final concentration) was added to quench the reaction and cells were incubated at room temperature for 5 min, followed by 15 min on ice before the cells were pelleted at 4 °C and washed in ice-cold PBS. Each sample was flash frozen in liquid nitrogen and stored at − 80 °C. Cells were lysed in a tight dounce homogenizer (ten cycles) with 3 ml of cold lysis buffer (10 mM Tris-HCl, pH 8, 10 mM NaCl, 0.2% Igepal CA-630, one tablet protease inhibitor cocktail (Roche complete, EDTA-free, 11873580001)). Cells were left on ice for 5 min and were then homogenized another ten times. The lysed cells, in 3 ml lysis buffer, were added to 47 ml of lysis buffer and incubated on ice for 30 min with occasional mixing. Chromatin was pelleted and resuspended in 1 ml of 1.25× NEBuffer 2 and then split into four samples. Each sample was then pelleted at 100g and resuspended in 358 µ l of 1.25× NEBuffer 2. SDS (11 µ l of 10%) was added and each tube was incubated at 37 °C for 60 min on a rotary mixer at 950 r.p.m. Samples were mixed by pipetting up and down every 15 min. SDS was quenched with 75 µ l 10% Triton X-100 and incubated at 37 °C for 60 min. HindIII digestion, biotinylation, ligation, cross-link reversal, promoter capture and library preparation were performed exactly as described 34 .
DNase I-seq data analysis. Alignment. DNase I-seq sequences from all experiments were mapped onto the reference human genome version hg38, with Bowtie version 2.3.1 (refs 24, 58 ) using default parameters. Low-quality reads were trimmed before alignment and the quality control statistics for the samples were obtained using FastQC tools. Reads that were aligned to unique chromosomal positions were retained.
Peak calling. DHSs were called with MACS2 using callpeak function (nomodel, call-summits and q = 0.005 parameters) 59 . DHSs were allocated to genes and to the gene promoter if they were within 2 kb of the gene transcription start site, and as distal otherwise. Overlaps between DHS peaks were defined by requiring the summits of two peaks to lie within ± 200 base pairs (bp).
DNase I-seq peak set definition. To define a common set of coordinates covering all the significant distal DHSs investigated in this study, we merged all the individual DNase I-seq reads for all of the AML samples assayed by DNase I-seq. This data set was then used to define the peak summits of 128,864 distal peaks, excluding promoters, which were detected in the merged data. This approach was designed to maximize the precision and sensitivity of peak detection, allowing us to generate a single set of peak coordinates that (1) included all the regions where peaks might be found, thereby reducing the level of false negatives, and (2) greatly diminished the number of false positives. The DNA read counts were then determined for 400-bp windows centered on each peak for each AML sample and for the PBSC samples. To account for the different number of reads in each of the samples; the read counts were initially normalized for total read depth using DEseq2 (ref. 60 ). Because most of our individual DNase I-seq data sets encompassed 25,000-40,000 significant distal DHSs, we further normalized the values obtained on the basis of the midpoint (12.5 percentile) of the top 25% of peaks (32,216 peaks) .
Mutation-specific DNase I-seq peak set definition. We determined the average log 2 values for seven distinct groups of AMLs that carried the same specific alterations in key regulators, and that shared similar patterns of DHSs based on DHS clustering analysis. The samples included in each group are color coded and listed in order in Supplementary Table 1 for AML samples with the following alterations: (1) three samples with FLT3-ITD but not NPM1 (1-3), (2) six samples with FLT3-ITD and NPM1 (1-6), (3) two samples with NPM1 but not FLT3-ITD (1 and 2), (4) four samples with t(8;21) (1-4), (5) three samples with inv(16) (1-3); (6) six samples with RUNX1 or RUNX1 and CEBPA (1-6), and (7) three samples with two CEBPA alterations (1-3). To define alteration-specific subsets of specific DHSs, we identified peaks where the average log 2 value was both ≥ 64 and at least three-fold higher than in PBSCs. Downregulated DHSs were defined as having at least threefold lower expression than in PBSCs. Samples were not included in these seven specific groups in cases where, for example, two copies of the FLT3-ITD alteration were present, the NPM1 alteration was paired with a NRAS instead of the FLT3-ITD, RUNX1 alterations were paired with a JAK2 alteration, or where only a single CEBPA allele was altered.
Clustering of DNase I-seq data. Clustering of DNase I-seq samples was carried out using the merged distal DHSs. The number of reads that mapped to these DHSs was counted in a 400-bp window centered on the DHS summit, and subsequently normalized to total sample size using DEseq2 (ref. 60 ). Pearson correlation coefficients were then calculated for each pair of samples using the log 2 of the normalized read counts, and were then hierarchically clustered using Euclidean distance and complete linkage clustering of the correlation matrix in R. For further analysis methods see Supplementary Material section 3 -Additional supplementary bioinformatics methods.
RNA-seq data analysis.
RNA-seq reads were aligned to the human genome hg38 build with STAR 61 using ENCODE recommend parameters. Separate density profiles for the positive and negative strands were generated using bedtools. Cufflinks 62 was used to calculate the expression values as fragments per kilobase per million aligned reads (FPKM) from the aligned RNA-seq data. Mutation-specific group gene-wise expression values were obtained using the cuffdiff function of cufflinks. The correlation between any two AML samples was obtained as the Pearson correlation coefficient of expression values over all genes. A correlation matrix was thus generated for all the samples and hierarchically clustered to study the relationship among samples as given in Fig. 1c . Smooth scatter plots were generated in R. For further analysis methods see Supplementary Material section 3 -Additional supplementary bioinformatics methods.
Promoter capture HiC data analysis. The CHi-C paired-end sequencing reads from ITD/NPM1-2 and t(8;21)-1R subjects and a publicly available CD34 + data set (accession numbers ERR436032 and ERR436025) were put through HiCUP pipeline 63 . The raw sequencing reads were separated and mapped against the human genome (hg38). The reads were then filtered for experimental artifacts and duplicate reads, and then re-paired. Statistically significant interactions were called using GOTHiC package 64 and HOMER software. This uses a cumulative binomial test to detect interactions between distal genomic loci that have significantly more reads than expected by chance, by using a background model of random interactions. This analysis assigns each interaction a P value, which represents its significance. Differential interactions were determined with HOMER 65 for t(8;21) using FLT3-ITD or CD34 + as background and FLT3-ITD using t(8;21) or CD34 + as background. A difference with P < 0.1 was deemed significant.
Transcription factor gene regulatory network construction. We identified a subset of 310 transcription factor genes that are expressed in one or more of our AML samples. The gene names for transcription factors in humans were obtained from AnimalTFDB 66 . The 310 transcription factors were considered as nodes and the nodes were colored according to their expression values at each AML subtype ( Fig. 6, Supplementary Fig. 9 and Supplementary Note Fig. SN5 ). Node border color signifies whether the gene was upregulated, downregulated or invariant based on a two-fold change compared to CD34 + cells. The node border type indicates whether a gene was differentially expressed in one AML subtype as compared to other subtypes. A directed edge from transcription factor a (TF a ) to TF b indicates motif binding of TF a to the locus encoding transcription factor TF b , and the edge is prominently displayed if TF a bound to the locus at that stage. The edge was classified and color coded according to the significance of motif count enrichment.
Motif count enrichment for transcription factor network. Initially footprints for each AML subtype were identified using the Wellington algorithm 29 and were annotated to their related promoter using CHi-C data where possible. Motif searches within footprint coordinates were performed using HOMER 65 . The number of motifs per transcription factor gene were counted and the significance of motif enrichment was identified using bootstrapping of random sampling; a random set of mapped motifs was extracted from all union footprinted motif of all AML subtypes and the CD34 + cells. After 1,000 iterations, the mean, standard deviation and z-scores were computed. Motif (TF a ) was linked to gene (TF b ) with positive z-score values only.
Motif count enrichment for upregulated transcription factors. The correlations (r e ) between all transcription factor genes based on FPKM values from the RNA-seq analysis were identified and the correlations (r m ) between all transcription factor genes based on motif count binding were identified. The correlation coefficients were z-transformed using Fisher z-transformation with FisherZ function in R. The average of the transformed z-scores of both gene expression and motif were transformed to correlation (r). All transcription factor genes with a correlation coefficient ≥ 0.3 were considered. Then, for each AML cell type, the differentially expressed transcription factor genes among these correlated genes were identified, first those of each AML subtype as compared to CD34 + cells and second those of all AML subtypes compared to the average expression of other subtypes including CD34 + cells. Upregulated genes with a two-fold change in expression compared to CD34 + cells or compared to other AMLs were considered to construct the network. Motif enrichment for the correlated and upregulated transcription factor genes and edges were identified as described above.
List of used position weight matrices. Motif curation is described the legend of Supplementary Table 2 .
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
